C-OOYD

FILE C-OOYD·COMPANY·CURATED BY ETERNAL SEARCH

HepaTx

stem cells, regenerative medicine, cell therapy

replacementreplacingcell therapy

hepatx.com·Palo Alto, California, United States·

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-OOYD

Projects

Proteomic assay for monitoring transplanted cells and tissues

exploratory

biomarker · high · Tue May 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Develop an assay platform to monitor transplanted cells and tissues and improve outcomes in cell-based therapies for liver and other diseases.

Proteomic assay development supported by an NIH/NIDDK SBIR Phase I grant, Award Number R43DK139879.

Awarded NIH SBIR Phase I grant titled “Development of a Proteomic Assay for Monitoring Transplanted Cells and Tissues” on 2025-05-20.

Off-the-shelf stem cell-based liver regenerative cell therapy

undisclosed

drug program · high · Thu Oct 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Develop regenerative cell therapies for patients with late-stage liver disease as an alternative to liver transplant.

Off-the-shelf stem cell-based cell therapy using regenerative medicine technologies, with emphasis on scalable manufacturing for liver regeneration.

CEO presentation announced for the UBS Virtual Organ Restoration and Cell Therapy Day on 2024-10-10.

Off-the-shelf stem cell-based liver regeneration therapy

undisclosed

drug program · high

Develop regenerative cell therapies for patients with late-stage liver disease as an alternative to liver transplant.

Off-the-shelf stem cell-based cell therapy for liver regeneration; supplied publication evidence discusses hepatocyte-like cells manufactured from mesenchymal stromal cells for liver disease.

Company site states HepaTx is developing off-the-shelf stem cell-based regenerative therapies and scalable manufacturing for liver regeneration; no specific clinical phase or candidate milestone is disclosed.

The supplied literature review states preclinical studies support effectiveness and recent clinical studies suggest cell replacement therapy can be safe and effective in liver disease, but no HepaTx-specific clinical result is provided.

Scalable manufacturing for regenerative liver cell therapies

undisclosed

platform · medium

Make stem cell-based liver regeneration clinically and economically practical through scalable manufacturing.

Manufacturing platform/process for off-the-shelf stem cell-based regenerative therapies for liver disease.

Company site emphasizes scalable manufacturing intended to support practical liver regeneration therapies; no named system, validation milestone, or deployment date is disclosed.

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence

Projects

Proteomic assay for monitoring transplanted cells and tissues

exploratory

biomarker · high · Tue May 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Develop an assay platform to monitor transplanted cells and tissues and improve outcomes in cell-based therapies for liver and other diseases.

Proteomic assay development supported by an NIH/NIDDK SBIR Phase I grant, Award Number R43DK139879.

Awarded NIH SBIR Phase I grant titled “Development of a Proteomic Assay for Monitoring Transplanted Cells and Tissues” on 2025-05-20.

Off-the-shelf stem cell-based liver regenerative cell therapy

undisclosed

drug program · high · Thu Oct 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Develop regenerative cell therapies for patients with late-stage liver disease as an alternative to liver transplant.

Off-the-shelf stem cell-based cell therapy using regenerative medicine technologies, with emphasis on scalable manufacturing for liver regeneration.

CEO presentation announced for the UBS Virtual Organ Restoration and Cell Therapy Day on 2024-10-10.

Off-the-shelf stem cell-based liver regeneration therapy

undisclosed

drug program · high

Develop regenerative cell therapies for patients with late-stage liver disease as an alternative to liver transplant.

Off-the-shelf stem cell-based cell therapy for liver regeneration; supplied publication evidence discusses hepatocyte-like cells manufactured from mesenchymal stromal cells for liver disease.

Scalable manufacturing for regenerative liver cell therapies

undisclosed

platform · medium

Make stem cell-based liver regeneration clinically and economically practical through scalable manufacturing.

Manufacturing platform/process for off-the-shelf stem cell-based regenerative therapies for liver disease.

Company site emphasizes scalable manufacturing intended to support practical liver regeneration therapies; no named system, validation milestone, or deployment date is disclosed.